Cargando…

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

BACKGROUND: While immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients and has dangerous side effects. The objective here was to identify the feasibility and mechanism of RAS/RAF/PI3K pathway inhibition in melanoma to sen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Chi, Saleh, Nabil, Yang, Jinming, Nebhan, Caroline A., Vilgelm, Anna E., Reddy, E. Premkumar, Roland, Joseph T., Johnson, Douglas B., Chen, Sheau-Chiann, Shattuck-Brandt, Rebecca L., Ayers, Gregory D., Richmond, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182921/ https://www.ncbi.nlm.nih.gov/pubmed/34092233 http://dx.doi.org/10.1186/s12943-021-01366-y

Ejemplares similares

Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma
por: Yan, Chi, et al.
Publicado: (2023)

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
por: Yan, Chi, et al.
Publicado: (2021)

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
por: Kumar, Amrendra, et al.
Publicado: (2023)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

MDM2 Antagonists Counteract Drug-Induced DNA Damage
por: Vilgelm, Anna E., et al.
Publicado: (2017)

The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo
por: Lavender, Nicole, et al.
Publicado: (2017)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Yan, Chi, et al.
Publicado: (2021)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

Cryo-EM structure of a RAS/RAF recruitment complex
por: Park, Eunyoung, et al.
Publicado: (2023)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin, Xiaoning, et al.
Publicado: (2021)

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors
por: Lai, Lick Pui, et al.
Publicado: (2022)

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

T cell leukemia control via Ras-Raf pathway inhibition with peptides
por: Marin, G, et al.
Publicado: (2017)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
por: Nolan, Aoife A., et al.
Publicado: (2021)

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
por: Vilgelm, Anna E., et al.
Publicado: (2019)

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
por: Singh, Manisha, et al.
Publicado: (2017)

Correction to: T cell leukemia control via Ras-Raf pathway inhibition with peptides
por: Marin, GH, et al.
Publicado: (2018)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
por: Dolatkhah, Roya, et al.
Publicado: (2021)

Publisher Correction: Cryo-EM structure of a RAS/RAF recruitment complex
por: Park, Eunyoung, et al.
Publicado: (2023)

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
por: Francis, David M., et al.
Publicado: (2020)

Intraparticle Double‐Scattering‐Decoded Sonogenetics for Augmenting Immune Checkpoint Blockade and CAR‐T Therapy
por: Wang, Duo, et al.
Publicado: (2022)

One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade
por: Xu, Xincheng, et al.
Publicado: (2023)

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
por: Zhang, Zhizhu, et al.
Publicado: (2022)

Harmine suppresses hyper-activated Ras–MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans
por: Ji, Jiaojiao, et al.
Publicado: (2019)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cmbp8et690k9gev2lt9t26tb6n